Patents by Inventor Bennett G. Childs

Bennett G. Childs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210169875
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: December 7, 2020
    Publication date: June 10, 2021
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Jan M.A. van Deursen, Darren J. Baker, Bennett G. Childs
  • Patent number: 10517866
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: December 31, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Patent number: 10478433
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 19, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M. A. van Deursen, Alain Philippe Vasserot, Bennett G. Childs
  • Patent number: 10478432
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: November 19, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Patent number: 10413542
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 17, 2019
    Assignees: Buck Institute for Research on Aging, Unity Biotechnology, Inc., Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Yi Zhu
  • Patent number: 10328058
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 25, 2019
    Assignees: Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc., Buck Institute for Research on Aging
    Inventors: Darren J. Baker, Marco Demaria, Albert Davalos, Bennett G. Childs, Jan M. A. van Deursen, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Remi-Martin Laberge, Judith Campisi
  • Patent number: 10328073
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: June 25, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Publication number: 20190022225
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.
    Type: Application
    Filed: June 13, 2018
    Publication date: January 24, 2019
    Inventors: Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen
  • Publication number: 20190022090
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: August 3, 2018
    Publication date: January 24, 2019
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • Publication number: 20190000846
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. This invention provides senolytic agents that remove senescent cells that are present in or around atherosclerotic plaques. The agents inhibit or reverse thinning of the fibrous cap on atherosclerotic plaques. This has the effect of stabilizing the plaques, inhibiting rupture and preventing pathological sequelae that manifest as coronary artery disease. Senolytic agents used in this way complement the action of statins and other drugs that cause plaque regression. Thus, senolytic agents and lipid lowering drugs can be used in combination for enhanced therapeutic effect.
    Type: Application
    Filed: July 2, 2018
    Publication date: January 3, 2019
    Inventors: Jan M.A. van Deursen, Bennett G. Childs, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Remi-Martin Laberge, Judith Campisi, Marco Demaria
  • Publication number: 20180256568
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 11, 2018
    Publication date: September 13, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer, Yi Zhu
  • Publication number: 20180250296
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 6, 2018
    Inventors: Remi-Martin Laberge, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • Publication number: 20180235957
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 23, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • Publication number: 20180193458
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 12, 2018
    Inventors: Jose Alberto Lopez-Dominguez, Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Yi Zhu
  • Patent number: 10010546
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 3, 2018
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Publication number: 20180104222
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.
    Type: Application
    Filed: October 24, 2017
    Publication date: April 19, 2018
    Inventors: Bennett G. Childs, Jan M.A. van Deursen
  • Publication number: 20170348307
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: July 12, 2017
    Publication date: December 7, 2017
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer
  • Publication number: 20170224680
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: January 28, 2015
    Publication date: August 10, 2017
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer
  • Publication number: 20170209435
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 27, 2017
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer
  • Publication number: 20170196857
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: March 10, 2017
    Publication date: July 13, 2017
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer